These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26587751)

  • 1. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution.
    Stoecklein NH; Fischer JC; Niederacher D; Terstappen LW
    Expert Rev Mol Diagn; 2016; 16(2):147-64. PubMed ID: 26587751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting.
    Fehm TN; Meier-Stiegen F; Driemel C; Jäger B; Reinhardt F; Naskou J; Franken A; Neubauer H; Neves RPL; van Dalum G; Ruckhäberle E; Niederacher D; Rox JM; Fischer JC; Stoecklein NH
    Cytometry A; 2018 Dec; 93(12):1213-1219. PubMed ID: 30551262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients.
    Fischer JC; Niederacher D; Topp SA; Honisch E; Schumacher S; Schmitz N; Zacarias Föhrding L; Vay C; Hoffmann I; Kasprowicz NS; Hepp PG; Mohrmann S; Nitz U; Stresemann A; Krahn T; Henze T; Griebsch E; Raba K; Rox JM; Wenzel F; Sproll C; Janni W; Fehm T; Klein CA; Knoefel WT; Stoecklein NH
    Proc Natl Acad Sci U S A; 2013 Oct; 110(41):16580-5. PubMed ID: 24065821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).
    Andree KC; Mentink A; Zeune LL; Terstappen LWMM; Stoecklein NH; Neves RP; Driemel C; Lampignano R; Yang L; Neubauer H; Fehm T; Fischer JC; Rossi E; Manicone M; Basso U; Marson P; Zamarchi R; Loriot Y; Lapierre V; Faugeroux V; Oulhen M; Farace F; Fowler G; Sousa Fontes M; Ebbs B; Lambros M; Crespo M; Flohr P; de Bono JS
    Int J Cancer; 2018 Nov; 143(10):2584-2591. PubMed ID: 30006930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.
    Franken A; Driemel C; Behrens B; Meier-Stiegen F; Endris V; Stenzinger A; Niederacher D; Fischer JC; Stoecklein NH; Ruckhaeberle E; Fehm T; Neubauer H
    Clin Chem; 2019 Apr; 65(4):549-558. PubMed ID: 30737205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.
    Tamminga M; Andree KC; van den Bos H; Hiltermann TJN; Mentink A; Spierings DCJ; Lansdorp P; Timens W; Schuuring E; Terstappen LWMM; Groen HJM
    Br J Cancer; 2022 Feb; 126(3):409-418. PubMed ID: 34848855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis.
    Stoecklein NH; Fluegen G; Guglielmi R; Neves RPL; Hackert T; Birgin E; Cieslik SA; Sudarsanam M; Driemel C; van Dalum G; Franken A; Niederacher D; Neubauer H; Fehm T; Rox JM; Böhme P; Häberle L; Göring W; Esposito I; Topp SA; Coumans FAW; Weitz J; Knoefel WT; Fischer JC; Bork U; Rahbari NN
    Mol Cancer; 2023 Nov; 22(1):181. PubMed ID: 37957606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.
    Rieckmann LM; Spohn M; Ruff L; Agorku D; Becker L; Borchers A; Krause J; O'Reilly R; Hille J; Velthaus-Rusik JL; Beumer N; Günther A; Willnow L; Imbusch CD; Iglauer P; Simon R; Franzenburg S; Winter H; Thomas M; Bokemeyer C; Gagliani N; Krebs CF; Sprick M; Hardt O; Riethdorf S; Trumpp A; Stoecklein NH; Peine S; Rosenstiel P; Pantel K; Loges S; Janning M
    Mol Cancer; 2024 May; 23(1):93. PubMed ID: 38720314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
    Mout L; van Dessel LF; Kraan J; de Jong AC; Neves RPL; Erkens-Schulze S; Beaufort CM; Sieuwerts AM; van Riet J; Woo TLC; de Wit R; Sleijfer S; Hamberg P; Sandberg Y; Te Boekhorst PAW; van de Werken HJG; Martens JWM; Stoecklein NH; van Weerden WM; Lolkema MP
    Eur J Cancer; 2021 Jun; 150():179-189. PubMed ID: 33932725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells (CTCs) as a liquid biopsy material and drug target.
    Cai LL; Ye HM; Zheng LM; Ruan RS; Tzeng CM
    Curr Drug Targets; 2014; 15(10):965-72. PubMed ID: 25182470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells as promising novel biomarkers in solid cancers.
    Lianidou ES; Strati A; Markou A
    Crit Rev Clin Lab Sci; 2014 Jun; 51(3):160-71. PubMed ID: 24641350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical validation of a new microfluidic device for enrichment of CTCs from large volumes of blood by using buffy coats to mimic diagnostic leukapheresis products.
    Guglielmi R; Lai Z; Raba K; van Dalum G; Wu J; Behrens B; Bhagat AAS; Knoefel WT; Neves RPL; Stoecklein NH
    Sci Rep; 2020 Nov; 10(1):20312. PubMed ID: 33219265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases.
    Mamdouhi T; Twomey JD; McSweeney KM; Zhang B
    Cancer Metastasis Rev; 2019 Jun; 38(1-2):297-305. PubMed ID: 31053984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine.
    Alberter B; Klein CA; Polzer B
    Expert Rev Mol Diagn; 2016; 16(1):25-38. PubMed ID: 26567956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Circulating tumor cells: liquid biopsy].
    Alix-Panabières C; Pierga JY
    Bull Cancer; 2014 Jan; 101(1):17-23. PubMed ID: 24445939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for Isolation and Molecular Profiling of Circulating Tumor Cells.
    Chen JY; Chang YC
    Adv Exp Med Biol; 2017; 994():43-66. PubMed ID: 28560667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells: a multifunctional biomarker.
    Yap TA; Lorente D; Omlin A; Olmos D; de Bono JS
    Clin Cancer Res; 2014 May; 20(10):2553-68. PubMed ID: 24831278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells.
    Mishra A; Dubash TD; Edd JF; Jewett MK; Garre SG; Karabacak NM; Rabe DC; Mutlu BR; Walsh JR; Kapur R; Stott SL; Maheswaran S; Haber DA; Toner M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):16839-16847. PubMed ID: 32641515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cell isolation and diagnostics: toward routine clinical use.
    van de Stolpe A; Pantel K; Sleijfer S; Terstappen LW; den Toonder JM
    Cancer Res; 2011 Sep; 71(18):5955-60. PubMed ID: 21896640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells: liquid biopsy of cancer.
    Alix-Panabières C; Pantel K
    Clin Chem; 2013 Jan; 59(1):110-8. PubMed ID: 23014601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.